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Summary
Background Atopic eczema is a common chronic inflammatory skin disease.
Research suggests an association between atopic eczema and obesity, with incon-
sistent evidence from European populations.
Objectives To explore the association between diagnosed atopic eczema and being
overweight or obese, and whether increased atopic eczema severity was associ-
ated with higher body mass index.
Methods We undertook a cross-sectional analysis within a cohort of adults
(matched by age, sex and general practice) with and without a diagnosis of ato-
pic eczema. We used primary care (Clinical Practice Research Datalink Gold) and
linked hospital admissions data (1998–2016). We used conditional logistic
regression to compare the odds of being overweight or obese (adjusting for con-
founders and potential mediators) in those with atopic eczema (mild, moderate
and severe, and all eczema) vs. those without.
Results We identified 441 746 people with atopic eczema, matched to 1 849 722
without. People with atopic eczema had slightly higher odds of being overweight
or obese vs. those without [odds ratio (OR) 108, 95% confidence interval (CI)
107–109] after adjusting for age, asthma and socioeconomic deprivation.
Adjusting for potential mediators (high-dose glucocorticoids, harmful alcohol
use, anxiety, depression, smoking) had a minimal impact on effect estimates (OR
107, 95% CI 106–108). We saw no evidence that odds of being overweight or
obese increased with increasing atopic eczema severity, and there was no associa-
tion in people with severe eczema.
Conclusions We found evidence of a small overall association between atopic
eczema and being overweight or obese. However, there was no association with
obesity among those with the most severe eczema. Our findings are largely reas-
suring for this prevalent patient group who may already have an increased risk
of cardiovascular disease.
What is already known about this topic?
• Research from North America and Asia suggests that atopic eczema is associated
with being overweight or obese; however, evidence from Europe is inconsistent.
• Atopic eczema symptoms, including chronic itch, may lead to sleep disturbance,
anxiety and depression, which may contribute to being overweight or obese,
through lifestyle exposures and inflammation.
• Only one small previous cross-sectional study has explored links between self-re-
ported atopic eczema severity and obesity.
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What does this study add?
• We found evidence of a small association between diagnosed atopic eczema and
being overweight or obese.
• However, in a large population-based study involving more than 2 million English
adults we found no association between severe atopic eczema and being over-
weight or obese.
• Our findings are reassuring for patients and practitioners. Based on this study, we
do not recommend any changes to clinical practice.
Atopic eczema is an increasingly common1 chronic inflamma-
tory skin condition affecting up to 10% of adults.2,3 At the
same time, obesity is a major global health challenge: 39% of
adults are overweight and 13% are obese.4 Obesity is a major
modifiable risk factor for numerous health conditions includ-
ing cardiovascular disease, cancer and diabetes.4 Atopic eczema
has also been linked to major adverse health outcomes includ-
ing cardiovascular disease;5,6 previous studies have proposed
that increased prevalence of cardiovascular risk factors, such as
being overweight or obese, may be an important contributory
factor.7 A meta-analysis reported an association between atopic
eczema and being overweight or obese in North American
and Asian studies, but no association in European popula-
tions.8
There are a number of potential explanations for an associa-
tion between atopic eczema and obesity. The symptoms asso-
ciated with atopic eczema could contribute to obesity; for
example, chronic itch can lead to sleep disturbance,9,10 which
could lead to weight gain and increased cardiovascular
risk.11,12 People with atopic eczema may avoid physical exer-
cise in order to avert the discomfort caused by sweating onto
inflamed skin.13 The role of the gut microbiome (the collec-
tive genomes of gut microbes) may also be relevant; however,
its role in obesity and in atopic eczema is not yet clearly
defined.14,15 In addition, treatment with glucocorticoids, or
the underlying systemic inflammation from atopic eczema
itself, could also lead to weight gain.7 Alternatively, factors
associated with obesity could contribute to atopic eczema,
including increased transepidermal water loss,16 and proin-
flammatory changes.17,18
Existing research has often been limited by using self-re-
ported rather than physician-diagnosed atopic eczema, and has
lacked important detail on how the association with being
overweight or obese varies by atopic eczema severity.8 Under-
standing how the relationship between atopic eczema and
being overweight or obese changes with atopic eczema sever-
ity could inform our understanding of underlying mecha-
nisms. We aimed to explore the association between
diagnosed atopic eczema and being overweight or obese, and
investigate the effect of increasing atopic eczema severity on
being overweight or obese.
Patients and methods
Study design and setting
We undertook a cross-sectional analysis of a cohort of adults,
with and without atopic eczema, identified in the Clinical
Practice Research Datalink Gold (CPRD Gold). CPRD contains
high-quality anonymized electronic health record data from
over 650 UK general practices.19 As the majority of the UK
population are registered with a general practitioner (GP),
CPRD provides a broadly representative population.19
GPs in England act as the gateway to health care. Most peo-
ple with atopic eczema in England are managed in primary
care by GPs,20 although individuals with moderate and severe
atopic eczema may be jointly managed with secondary care by
dermatologists. We also used linked hospital admissions data
from Hospital Episode Statistics (HES). HES includes data on
all National Health Service-funded hospital admissions in Eng-
land.21 Seventy-five per cent of English practices contributing
to CPRD are eligible for linkage with HES.19
The study was approved by the London School of Hygiene
and Tropical Medicine Research Ethics Committee (Reference
11961-2) and by the CPRD Independent Scientific Advisory
Committee (Protocol Number: 16_100RA).
Study population
We identified a matched cohort of adults (aged 18 years and
over), with and without a diagnosis of atopic eczema, with a
valid body mass index (BMI) measure recorded in primary
care. Individuals eligible for study inclusion were those regis-
tered with CPRD practices eligible for linkage with HES data.
Individuals were required to have at least 12 months of regis-
tration (to allow adequate timing for recording of baseline
health status), and to have at least one record of BMI (full eli-
gibility criteria are available in Appendix S1; see Supporting
Information). Figure 1 shows a visual representation of cohort
entry and exit.
We identified all individuals with atopic eczema based on a
validated algorithm requiring primary or secondary care
records of at least one diagnostic atopic eczema code and at
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least two atopic eczema therapies (including prescribing and
phototherapy) recorded on separate days (Appendix S1).22
We defined the date of atopic eczema diagnosis as the date at
which the individual fulfilled the full atopic eczema algorithm
(latest of atopic eczema diagnosis code or second atopic
eczema therapy record).
Individuals with atopic eczema were matched (without
replacement) with up to five individuals without atopic
eczema on age, sex and GP practice, in calendar date order
(i.e. individuals in the matched cohort were assigned first to
those with earliest cohort entry to avoid time-related bias).
We used a 15-year age-matching window to minimize poten-
tial selection bias introduced by excluding unmatched individ-
uals (we adjusted for age to account for this wide window).
Outcome
We defined individuals as being overweight or obese if their
BMI was 25 kg m–2 or more based on the World Health
Organization definition (overweight: BMI ≥ 25 kg m–2
and < 30 kg m–2; obese: ≥ 30 kg m–2).4 We compared over-
weight and obese individuals with those who were under-
weight or normal weight (underweight: < 185 kg m–2;
normal weight: ≥ 185 kg m–2 and < 25 kg m–2) (further
details in Figure 1 and Appendix S1).
Covariates
We used a directed acyclic graph (Appendix S2; see Support-
ing Information) to visualize the relationships between atopic
eczema (exposure), BMI (outcome), and potential
confounders or mediators.23 We considered the following as
potential confounders of the association between atopic
eczema and increased BMI: age, sex, socioeconomic depriva-
tion and asthma.
We used quintiles of index of multiple deprivation (IMD)
to capture socioeconomic deprivation.24 We defined asthma as
any diagnostic code for asthma recorded in primary or sec-
ondary care on or before cohort entry. We considered the fol-
lowing as possible mediators: smoking,25 depression,26
anxiety,27 harmful alcohol use,28 and high-dose oral glucocor-
ticoid use. To fulfil our depression or anxiety definitions, we
required that individuals had at least one diagnostic code for
anxiety (generalized anxiety disorder or panic disorder) or
depression in either primary or secondary care on or before
cohort entry date. We defined high-dose oral glucocorticoid
use as a prescription for an oral glucocorticoid equivalent to
20 mg or more per day of prednisolone prescribed on or
before cohort entry date.
Full details of all covariate definitions are in Appendix S1.
We also considered ethnicity as a potential confounder,3 but
only adjusted for it in a sensitivity analysis (Appendix S3, sen-
sitivity analysis; see Supporting Information) restricting to
those entering the cohort from 2006 when ethnicity data were
more complete.29 Complete morbidity code lists for all vari-
ables are available to download at https://doi.org/10.17037/
DATA.00000918.
Statistical analyses
We undertook all analyses using Stata Statistical Software,
Release 151 (StataCorp LLC, College Station, TX, USA).
Figure 1 Visual representation of cohort entry and exit, and calculation of body mass index (BMI, kg m–2)
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Main analysis
We used logistic regression, conditional on matched set, to
estimate odds ratios (ORs) [95% confidence intervals (CIs)]
comparing the odds of being overweight or obese between
those with atopic eczema and those without. We initially fitted
minimally adjusted models adjusting explicitly for age (in 5-
year bands), and implicitly for sex and GP practice (through
matching). We then additionally adjusted for potential con-
founders (IMD and asthma). Finally, we further adjusted for
potential mediators of the relationship between atopic eczema
and being overweight or obese (anxiety, depression, harmful
alcohol use, high-dose oral glucocorticoid use and smoking
status). Smoking data were missing for some individuals, so
we performed a complete-case analysis, preserving matching
by further excluding any individuals who were unmatched as
a result.
Sensitivity analyses
We tested the robustness of our findings by repeating the
main analysis in a series of sensitivity analyses: (i) excluding
underweight individuals, whose association with atopic
eczema may be qualitatively different from normal-weight
individuals, masking an association between atopic eczema
and being overweight or obese; (ii) excluding overweight
individuals, as atopic eczema may be more strongly associated
with being obese than with being overweight; (iii) restricting
cohort entry to 2004, when BMI was more completely
recorded, to minimize potential selection bias; (iv) excluding
women of childbearing age (18–45 years) who may have a
recorded weight increase due to pregnancy; and (v) adjusting
for possible confounding effects of ethnicity, restricting to
individuals entering the cohort from 2006 when ethnicity was
more completely recorded (Appendix S3, sensitivity analysis).
Secondary analyses
We conducted two secondary analyses to investigate: (i) the
association between atopic eczema severity and BMI; and (ii)
whether the association between atopic eczema and BMI was
modified by sex (studies suggest the association is stronger in
women than men30).
We defined atopic eczema severity using records for atopic
eczema therapies and referral with atopic eczema to a derma-
tologist. Individuals with atopic eczema were considered to
have mild atopic eczema by default; moderate eczema if pre-
scribed two potent topical steroids (within one year) or a
topical calcineurin inhibitor; or severe eczema if given pho-
totherapy, systemic treatment, or referred to a dermatologist
(details in Appendix S1). We defined atopic eczema severity
using all information recorded on or before cohort entry. We
compared the odds of being overweight/obese in individuals
with mild, moderate and severe atopic eczema with those
who had no atopic eczema.
Results
We identified a cohort of 441 746 adults with atopic eczema,
matched to 1 849 722 without (Figure 2). Individuals with
and without atopic eczema had similar smoking status and
level of socioeconomic deprivation (Table 1). People with ato-
pic eczema were more likely to have an asthma diagnosis than
were individuals without atopic eczema (234% vs. 124%).
The proportion of individuals with missing smoking status
was similar for individuals with and without atopic eczema.
Individuals excluded, due to missing or improbable BMI infor-
mation, were likely to be younger and have less follow-up
time than those included in the study cohort (Appendix S3,
missing data; see Supporting Information).
The proportion of people who were overweight or obese
was similar in those with atopic eczema (563%) and without
(553%). After adjusting for age, people with atopic eczema
had 10% higher odds (OR 110, 95% CI 110–111) of being
overweight or obese than those without atopic eczema. The
association between atopic eczema and increased BMI attenu-
ated slightly (although 95% CIs overlapped) after additionally
adjusting for asthma and socioeconomic deprivation (OR
108, 95% CI 107–109). Further adjusting for potential
mediators (high-dose oral glucocorticoid use, harmful alcohol
use, anxiety, depression and smoking) made little difference
to the point estimate (OR 107, 95% CI 106–108)
(Table 2).
Sensitivity analyses
The results of our sensitivity analyses were broadly similar to
the results of the main analysis and did not change our con-
clusions (Appendix S3, sensitivity analysis).
Secondary analyses
After adjusting for age, asthma and socioeconomic depriva-
tion, compared with individuals without atopic eczema: (i) in
people with mild atopic eczema we found evidence of a small
increased risk of being overweight or obese (OR 106, 95%
CI 105–107); (ii) having moderate atopic eczema was asso-
ciated with 14% higher odds (OR 114, 95% CI 113–116)
of being overweight or obese; but (iii) there was no evidence
of an association between severe atopic eczema and being
overweight or obese (OR 100, 95% CI 096–103) [Figure 3;
Appendix S3, association between atopic eczema severity and
being overweight or obese (see Supporting Information)].
There was strong evidence (Wald test P < 0001) against
homogeneity in the effect sizes for mild, moderate and severe
atopic eczema compared with no atopic eczema.
We found evidence (P < 0001) that sex modified the asso-
ciation between atopic eczema and increased BMI; however,
the difference in estimates was very small. After adjusting for
age, socioeconomic deprivation and asthma, women with ato-
pic eczema were slightly more likely than men with atopic
© 2020 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2020)
4 Atopic eczema and obesity, A. Ascott et al.
Figure 2 Flowchart illustrating identification of study participants. CPRD, Clinical Practice Research Datalink; HES, Hospital Episode Statistics; BMI,
body mass index (kg m–2). aNumbers of individuals with and without eczema do not necessarily sum to the total number of individuals included,
as individuals with eczema could be included in the matched comparison cohort up until the date of their first eczema diagnosis. bCohort used in
model adjusted for potential mediators (anxiety, depression, harmful alcohol use, high-dose oral glucocorticoid use and smoking status).
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eczema to be overweight or obese (women: OR 109, 95% CI
108–110; men: OR 106, 95% CI 104–107).
Discussion
In our cross-sectional analysis of a large, population-based
cohort, we found a small association between diagnosed ato-
pic eczema and being overweight or obese. However, there
was no association between severe atopic eczema and being
overweight or obese, and there was evidence against homo-
geneity by atopic eczema severity. Over half of our study pop-
ulation, regardless of atopic eczema status, were overweight
or obese.
Our study is the first to examine the association between
physician-diagnosed atopic eczema and being overweight or
obese in a large population-based European study. A meta-
analysis looking at adult atopic eczema and being overweight
or obese estimated a pooled OR of 129 (95% CI 105–159),
and while our point estimate was smaller (107, 95% CI
106–108) it was within the confidence limits of the meta-
analysis.8 However, after stratifying by region, the meta-analy-
sis found no evidence of an association in European studies.8
Our results are consistent with a single US study that
assessed the association with obesity by disease severity.31
While the previous US study of severity was based on self-re-
ported eczema, the authors found results consistent with ours,
Table 1 Characteristics of individuals with and without atopic eczema
Characteristic
Without atopic eczema
n = 1 849 722
With atopic eczema
n = 441 746
Follow-up (years), median (IQR) 5 (20–97) 55 (23–103)
Age on cohort entry (years), median (IQR) 466 (321–627) 457 (303–636)
Female 1 167 224 (631) 273 322 (619)
Index of multiple deprivation
1 (least deprived) 442 288 (239) 105 746 (239)
2 425 555 (230) 101 411 (230)
3 366 117 (198) 86 776 (196)
4 352 822 (191) 84 646 (192)
5 (most deprived) 262 940 (142) 63 170 (143)
Asthma 229 217 (124) 103 482 (234)
Smoking status
Current or ex-smoking 887 579 (480) 220 308 (499)
Never smoking 953 803 (516) 220 049 (498)
Missing smoking data 8340 (05) 1389 (03)
BMI (kg m–2)
Underweight (< 185) 53 203 (29) 12 668 (29)
Normal (185–249) 767 939 (415) 178 507 (404)
Overweight (250–299) 623 207 (337) 147 071 (333)
Obese (≥ 300) 405 373 (219) 103 500 (234)
Numbers are n (%) unless otherwise stated. IQR, interquartile range; BMI, body mass index.
Table 2 Association between atopic eczema and being overweight/obese [all models implicitly adjusted for sex and general practice due to
matching]
Models implicitly adjusted for sex and general practice (due to
matching)
Model additionally adjusted for potential
mediators (high-dose glucocorticoids, harmful



















participants OR (95% CI)
No atopic eczema 1 849 722 1 028 580 100 (ref) 100 (ref) 1 837 490 1 022 881 100 (ref)
Atopic eczema 441 746 250 571 110 (110–111) 108 (107–109) 440 122 249 766 107 (106–108)
OR, odds ratio; CI, confidence interval; IMD, index of multiple deprivation. aRestricted to individuals with smoking status available and in
valid matched sets (i.e. including at least one individual with atopic eczema and one without).
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where the strongest association was seen between moderate
atopic eczema and obesity, and no association between severe
atopic eczema and raised BMI,31 suggesting that this unusual
pattern of association may be consistent in both English and
US populations. We saw a slightly stronger association
between atopic eczema and being overweight or obese in
women than men. While the difference in effect size was
small and unlikely to be clinically significant, this finding is
consistent with findings from other studies.30,32,33 A potential
explanation may be that women have a higher proportion of
body fat than men.
While the magnitude of association seen in this study was
small, there are a number of potential mechanisms for an
association between atopic eczema and obesity. Obesity is a
proinflammatory state, and atopic eczema is a chronic sys-
temic inflammatory disease.34 There may be behavioural
changes related to atopic eczema, such as a lack of physical
activity due to discomfort from sweating onto inflamed skin,
or impaired quality of life and sleep problems.9 There is also
an association between atopic eczema and other factors associ-
ated with increased weight including high-dose oral glucocor-
ticoid use, anxiety and depression,35 and increased alcohol
use,28 although additionally adjusting for these made little dif-
ference to the point estimate, suggesting that these mediators
had little effect on the relationship between atopic eczema and
overweight or obesity. Asthma (a common disease often
comorbid with atopic eczema) is associated with obesity, and
this association has been found to be stronger in women.36–38
Adjusting for asthma in our analysis only slightly attenuated
the magnitude of association, suggesting that the small associ-
ation between atopic eczema and being overweight or obese
is independent of asthma comorbidity.
It is possible that raised BMI may predispose to atopic
eczema. Adipose tissue is an endocrine organ, and leptin or
oestrogen (found in higher concentrations in women)39 may
modulate the immune profile towards T-helper 2 (cells that
help regulate the immune response) dominance,40 an
immunoprofile seen in atopic eczema.41 Obesity itself may
reduce the epidermal barrier function due to increased
sweating and blood pressure,16 increased transepidermal water
loss and changes to cutaneous lipid profiles.42 A recent Men-
delian randomization study supports this ‘reverse directional-
ity’ of causation: increasing BMI was found to have a small
causal association with atopic eczema; however, there was
weak evidence that atopic eczema conferred a greater risk of
raised BMI.43 Similar results have been found in psoriasis (a
distinct inflammatory skin condition).44 Therefore, it is possi-
ble that the relationship between atopic eczema and obesity is
bidirectional.
Our findings of the lack of dose–response relationship for
the association between eczema severity and BMI were consis-
tent with those of another study in a different population,
using different methodology. This may suggest that the rela-
tionship is not causal, or is nonlinear. One explanation for the
unusual relationship might be that people with severe atopic
eczema may have a tendency towards food avoidance – sec-
ondary to real or perceived food allergy – leading to weight
loss.45 Finally, atopic eczema is a heterogeneous disease, and
different subtypes may have variation in their underlying
mechanisms and effect on weight.46 The possibility of a non-
linear relationship between atopic eczema and obesity should
be tested with further research using BMI as a continuous
variable.
Our study has a number of strengths. We used a validated
algorithm to identify atopic eczema.22 Our atopic eczema and
BMI definitions were physician diagnosed, rather than self-re-
ported, avoiding bias introduced by self-report. We were also
able to explore the effect of atopic eczema severity. Our study
was population based, increasing the generalizability of our
results. Our large sample size allowed us to calculate effect
sizes with precision. At the same time, our study also had lim-
itations. We were unable to provide information on temporal-
ity due to our cross-sectional design. However, in order to
account for temporality as far as possible within the cross-sec-
tional design, we selected covariates if they preceded cohort
entry, and preferentially took weight measurements close to
cohort entry. We considered physical activity, and food allergy
or food avoidance, to be potential mediating factors; however,
Figure 3 Association between atopic eczema and being overweight or obese, by severity of atopic eczema compared with people without atopic
eczema. All models are implicitly adjusted for sex and general practice due to matching. Minimally adjusted: adjusted for age; fully adjusted: adjusted
for age, socioeconomic deprivation, asthma. Model additionally adjusted for potential mediators: adjusted for age, socioeconomic deprivation, asthma,
high-dose oral glucocorticoid use, harmful alcohol use, anxiety, depression and smoking. OR, odds ratio; CI, confidence interval
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as these could not be reliably captured in CPRD, we could not
account for them. Similarly, we could not capture undiag-
nosed, misdiagnosed or unrecorded atopic eczema. There may
be bias in our estimates if individuals who were excluded
from our analyses due to missing BMI measurements were
systematically more or less likely to be overweight/obese and
to have atopic eczema than the individuals who were
included. However, in a sensitivity analysis – restricting to
more recent data when BMI recording was more complete –
our results were unchanged, providing some assurance against
bias due to missing BMI data.
In conclusion, this large, population-based study suggests a
small association between atopic eczema and being overweight
or obese. In a secondary analysis, we found no association
between the most severe atopic eczema and being overweight
or obese. The underlying mechanism for this small association
remains unclear. As previous studies have reported that people
with severe atopic eczema are already at higher risk of cardio-
vascular disease,5,6 our findings are largely reassuring for
patients and practitioners.
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